tmax in EEA applications [Surveys]

posted by Helmut Homepage – Vienna, Austria, 2013-06-22 20:40 (3932 d 15:27 ago) – Posting: # 10865
Views: 6,256

Dear all,

with the IR GL operational for almost three years now and the MR GL approaching (see also this post) I’m curious what is your practice. I’m talking only about formulations where tmax is clinical relevant (mostly rapid onset, rarely AE related).
We all know that “A statistical evaluation of tmax is not required.” Does that mean that it is not accept­able as well? I read that “A non-parametric analysis is not acceptable”, but

<nitpicking>
this paragraph is related to ANOVA and log-transformation.
</nitpicking>

“[…] there should be no apparent* difference in median tmax and its X between test and reference product.”
where X = “variability” (IR GL) and “range” (MR draft).

My practice (as it was since the mid 1980s):Experience so far: no problems.

Questions:
1. What do you do now? _____________
2. Do you consider changing your practice in the near future? [ ] yes [ ] no
3. If yes, what are you planning to do? _____________



Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,636 registered users;
102 visitors (0 registered, 102 guests [including 8 identified bots]).
Forum time: 11:07 CET (Europe/Vienna)

With four parameters I can fit an elephant,
and with five I can make him wiggle his trunk.    John von Neumann

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5